Author

P. Nenclares

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Organism:mouse· 2 Assay:proteomics· 2

Frequent Co-Authors

K. J. Harrington· 4 shared A. Melcher· 3 shared A. Rullan· 3 shared E. C. Patin· 3 shared J. Kyula· 3 shared M. McLaughlin· 3 shared M. Pedersen· 3 shared S. Foo· 3 shared

Activity by Year

2022-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

K. J. Harrington

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T cell receptor signalling.

E. Armstrong, M. K. L. Chiu, S. Foo, L. Appleton, P. Nenclares, A. Patrikeev, N. Mohan, M. McLaughlin, G. Bozhanova, J. Hoebart, V. Roulstone, E. C. Patin, M. Pedersen, J. Kyula, F. Errington-Mais, , V. A. Jennings

This study shows that combining oncolytic Maraba virus with PD-1 blockade overcomes resistance in advanced melanoma with a cold tumor microenvironment.

bioRxiv · Apr 2, 2024Cancer Biology

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent anti-PD-L1- and anti-NKG2A-based adjuvant immunotherapy

E. C. Patin, P. Nenclares, C. Chan Wah Hak, M. T. Dillon, A. Patrikeev, M. McLaughlin, L. Grove, S. Foo, H. Soliman, J. P. Barata, J. Marsden, H. Baldock, V. Roulstone, J. Kyula, A. Burley, , K. J. Harrington

This study combines ATR inhibition with radiotherapy and immune checkpoint blockade to enhance antitumour immunity in HNSCC preclinical models.

bioRxiv · Nov 8, 2023 · PreprintImmunology

Cancer cell - fibroblast crosstalk via HB-EGF/EGFR/MEK signalling promotes macrophage recruitment in squamous cell carcinoma

G. Giangreco, A. Rullan, Y. Naito, D. Biwas, Y.-H. Liu, S. Hooper, P. Nenclares, S. Bhide, M. Cheang, P. Chakravarty, E. Hirata, C. Swanton, A. Melcher, K. Harrington, E. Sahai

The paper identifies a gene expression signature of cancer-fibroblast crosstalk in squamous cell carcinoma and shows its prognostic relevance and role in macrophage recruitment.

bioRxiv · Jul 13, 2023 · PreprintCancer Biology

FUME-TCRseq: Sensitive and accurate sequencing of the T-cell receptor from limited input of degraded RNA

A.-M. Baker, G. Nageswaran, P. Nenclares, T. Ronel, K. Smith, C. Kimberley, M. M. Lacle, S. Bhide, K. J. Harrington, A. Melcher, M. Rodriguez-Justo, B. Chain, T. A. Graham

FUME-TCRseq is a sensitive and accurate method for TCR sequencing from low-quality RNA, outperforming existing methods in detecting clonotypes and enabling analysis of archival tissue samples.

bioRxiv · Apr 24, 2023 · PreprintImmunology

CDK4/6 inhibition and dsRNA sensor agonism co-operate to enhance anti-cancer effects through ER stress and immune modulation of tumour cells

V. Roulstone, J. Kyula, J. Wright, L. Yu, A. Barreiro Alonso, M. Melake, J. Choudhary, R. Elliott, C. J. Lord, D. Mansfield, N. Matthews, R. Chauhan, V. Jennings, C. Chan, H. Baldock, , K. J. Harrington

bioRxiv · Sep 28, 2022 · PreprintCancer Biology